MDLZ trades near its 200‑day moving average with a bullish MACD crossover and a 3.4% dividend yield supporting valuation; Barclays and JP Morgan price targets of $72/$71 imply ~15% upside. Quarterly earnings guidance remains solid, reinforcing the overweight stance.

Analyst coverage stays overwhelmingly positive, with two major banks maintaining overweight and raising targets, fueling strong investor sentiment. The stock benefits from a resilient snack portfolio amid broader beverage sector volatility.

Long‑term risks are limited to commodity cost pressure, but MDLZ’s global brand moat and consistent cash flow sustain dividend safety. The outlook remains favorable as the company continues expanding high‑margin categories.

Technical data show MDLZ above its 50‑day SMA, RSI at 56, and a recent high‑volume breakout confirming upward momentum. The signal aligns with the implied ~12‑15% price appreciation from analyst targets.